« Back
Home /
Bulevirtide

Bulevirtide

Item no.	HY-P3465-1ea
Manufacturer	MedChem Express
CASRN	2012558-47-1
Amount	1 ea
Quantity options	10 mg 1 ea 1 mg 25 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.16
Formula	C30H36F2N8O
Citations	[1]Masetti C, et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int. 2021 Jul;41(7):1441-1442.\|[2]Cheng D, et al. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat. 2021 Jun;28(6):852-858.\|[3]Donkers JM, et al., Mechanistic insights into the inhibition of NTCP by myrcludex B. JHEP Rep. 2019 Aug 1;1(4):278-285.\|[4]Volz T, et al., The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013 May;58(5):861-7.\|[5]Zhao K, et al., Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect. 2018 Nov 21;7(1):186.
Smiles	O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](C(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CC(N)=O)C(N2[C@@H](CCC2)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=CC=C4)C(N5[C@@H](CCC5)C(N[C@@H](CC(O)=O)C(N[C@@H](CC6=CNC=N6)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N7[C@@H](CCC7)C(N[C@@H](C)C(N[C@@H](CC8=CC=CC=C8)C(NCC(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(N)=O)C(N9[C@@H](CCC9)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%10=CNC%11=CC=CC=C%10%11)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%12=CC=CC=C%12)C(N[C@@H](CC(N)=O)C(N%13[C@@H](CCC%13)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%14=CNC=N%14)C(N[C@@H](CC%15=CNC%16=CC=CC=C%15%16)C(N%17[C@@H](CCC%17)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(NCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CNC(CCCCCCCCCCCCC)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Myrcludex B
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	HBV
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Molecular Weight	5398.86
Product Description	Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2].
Manufacturer - Research Area	Infection
Solubility	DMSO: 50 mg/mL (ultrasonic)\|H2O: 83.33 mg/mL (ultrasonic; adjust pH to 8 with NH3·H2O)
Manufacturer - Pathway	Anti-infection
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P3465-1ea-safety-datasheet.pdf